198 related articles for article (PubMed ID: 23647713)
21. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
22. [The predictive factors of good glycaemic control in Chinese patients receiving biphasic insulin as part 30: a subgroup analyses from the A1 chieve study].
Hong J; Lei M; Chang B; Gao Z; Wang Z; Zhang X; Zhuang X; Chen B; Xu M; Yang W
Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):705-10. PubMed ID: 26674627
[TBL] [Abstract][Full Text] [Related]
23. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus.
Cucinotta D; Caputo S; Mannucci E; Nicolucci A; Pellegrini F; Perriello G; Sbraccia P
Minerva Endocrinol; 2012 Dec; 37(4):357-66. PubMed ID: 23235191
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
26. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
27. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
28. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
29. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Mahmood S; Vohra EA
J Pak Med Assoc; 2013 Oct; 63(10):1290-4. PubMed ID: 24392563
[TBL] [Abstract][Full Text] [Related]
30. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
Tamás G; Marre M; Astorga R; Dedov I; Jacobsen J; Lindholm A;
Diabetes Res Clin Pract; 2001 Nov; 54(2):105-14. PubMed ID: 11640994
[TBL] [Abstract][Full Text] [Related]
31. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
32. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.
Kumar A; Sharma SK; Rajput R; Unnikrishnan AG
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):16-20. PubMed ID: 24482982
[TBL] [Abstract][Full Text] [Related]
33. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
34. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M; Kaltoft MS; Lawson J; Nielsen LL; Strojek K; Tabak Ö; Jacob S
Diabetes Obes Metab; 2022 Sep; 24(9):1788-1799. PubMed ID: 35546450
[TBL] [Abstract][Full Text] [Related]
35. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Hanefeld M; Traylor L; Gao L; Landgraf W
Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
[TBL] [Abstract][Full Text] [Related]
38. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).
Shah S; Yang W; Hasan MI; Malek R; Molskov Bech O; Home P
Diabetes Technol Ther; 2013 Nov; 15(11):954-63. PubMed ID: 24053450
[TBL] [Abstract][Full Text] [Related]
39. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trial.
Oyer DS; Shepherd MD; Coulter FC; Bhargava A; Deluzio AJ; Chu PL; Trippe BS;
Clin Ther; 2011 Jul; 33(7):874-83. PubMed ID: 21741089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]